Phase 2 randomized, dose-ranging trial of CTP-543, a selective Janus Kinase inhibitor, in moderate-to-severe alopecia areataBrett King, James V. Cassella, Steve Kempers et al.|Journal of the American Academy of Dermatology|2022Cited by 80
Development of the alopecia areata scale for clinical use: Results of an academic–industry collaborative effortBrett King, Maryanne M. Senna, Natasha Atanaskova Mesinkovska et al.|Journal of the American Academy of Dermatology|2021Cited by 79